Health authorities in the U.S. and Canada are warning against the rapid expansion of injectable peptide sales despite a lack of clinical evidence [1].
The surge in usage matters because these substances are often sold through unregulated channels, bypassing the safety protocols required for pharmaceutical drugs. As consumers seek anti-aging and performance enhancements, they risk using contaminated or incorrectly dosed products.
In mid-April 2026, Health Canada issued a formal warning advising the public not to buy or use unauthorized injectable peptide drugs [2]. The agency's caution follows a trend where wellness and anti-aging clinics across North America market these substances as shortcuts to healing and youth [3].
Online marketplaces have become primary hubs for these transactions. Hundreds of sellers are currently offering injectable peptides to consumers globally [1]. To investigate the legitimacy of these products, CBC News purchased three unauthorized injectable peptide products for testing [2].
The market boom in 2026 is driven by viral claims regarding the benefits of peptides for muscle growth and longevity [4]. However, regulatory responses remain fragmented. While Health Canada maintains a strict warning against unauthorized use [2], the U.S. Food and Drug Administration is weighing the possibility of easing limits on compounded peptides to address the wellness boom [3].
Medical experts said that the underground market for compounded drugs often operates with limited oversight [5]. This gap allows sellers to claim benefits that are not supported by solid scientific evidence [1]. Because these products are injectable, the risk of infection or systemic adverse reactions is higher than with oral supplements [5].
“Hundreds of sellers are offering injectable peptides online”
The divergence between Health Canada's warnings and the FDA's consideration of eased limits highlights a regulatory tension. As the 'wellness' industry pushes the boundaries of pharmaceutical compounding, health agencies are struggling to balance patient access to innovative treatments with the need to prevent a public health crisis driven by unverified, injectable substances.
